Floatz logo

Samuraciclib

Metastatic Breast Cancer

PfizerSmall moleculePhase 2Active
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
73/ 100

Competitive context

890 Active assets in the Metastatic Breast Cancer cohort.

Asset / SponsorPhaseRating
Lapatinib
University of New Mexico
Phase 3BBB
Darolutamide
Vandana Abramson
Phase 2BBB
Trastuzumab Duocarmazine
Byondis B.V.
Phase 3BB
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
SWOG Cancer Research Network
Phase 4BB
Palbociclib
Hoffmann-La Roche
Phase 4BB

View all 50 →

Same molecule, other indications

Samuraciclib is also rated in:

pancreatic ductal adenocarcinomaDormant
CCC
Indicative ·
54 / 100
View asset →
Advanced Solid MalignanciesDormant
CCC
Indicative ·
48 / 100
View asset →
estrogen-receptor positive breast cancerDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →